AUPH - Aurinia Pharmaceuticals Inc logo

Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals develops and commercializes therapies for autoimmune diseases. Its primary product, LUPKYNIS, is an oral treatment for active lupus nephritis, while also working on aritinercept for other autoimmune conditions.

โš•๏ธ Healthcare NASDAQ Listed 1999 $ USD
$1,000 invested 20 years ago โ†’$516,779today

Score Overview

1 Year
Score
Net Growth9.42%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth13.67%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score9.2
Net Growth273.66%
Net TrendEvery year
Net Income Consistencyโ€”
Rev Growth7x
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Score
Net Growth15x
Net Trend60%
Net Income Consistency
Rev Growth1859x
Rev Trend88%
Revenue Consistency
20 Years
Score4.8
Net Growth15x
Net Trend55%
Net Income Consistency
Rev Growth91x
Rev Trend56%
Revenue Consistency
All Time
Score
Net Growth259x
Net Trend48%
Net Income Consistency
Rev Growth236x
Rev Trend52%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Aurinia Pharmaceuticals Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • AUPH

2010: 98.1% ยท 2021: 100.5% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-17
$ 15.40โ€”
1 Year2025-11-17
$ 15.49-0.58%
5 Years2021-11-17
$ 29.20-47.26%
10 Years2016-11-17
$ 3.43348.98%
20 Years2006-11-17
$ 0.03516x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 321M$ 314M$ 486M
2025$ 283M$ 287M$ 397M
2024$ 235M$ 5M$ 358M
2023$ 175M-$ 78M$ 350M
2022$ 134M-$ 108M$ 389M
2021$ 45M-$ 180M$ 466M
2020$ 50M-$ 102M$ 398M
2019-$ 88M$ 306M
2018$ 463K-$ 64M$ 125M
2017$ 420K-$ 70M$ 173M
2016$ 173K-$ 23M$ 39M
2015$ 235K-$ 18M$ 15M
2014$ 278K-$ 16M$ 32M
2013$ 948.56K-$ 2M$ 1M
2012$ 6M-$ 9M$ 184.96K
2011$ 927.52K-$ 2M$ 5M
2010$ 3M-$ 3M$ 6M
2009$ 4M-$ 7M$ 4M
2008$ 3M-$ 15M$ 21M
2007$ 2M-$ 33M$ 32M
2006$ 3M-$ 22M$ 22M
2005$ 1M-$ 29M$ 45M
2004$ 1M-$ 22M$ 50M
2003$ 7M-$ 14M$ 62M
2002$ 11M-$ 365.87K$ 40M
2001$ 5M-$ 7M$ 33M
2000$ 902.77K-$ 6M$ 11M
IPO1999$ 1M-$ 1M$ 2M
AUPH - Aurinia Pharmaceuticals Inc logo

Aurinia Pharmaceuticals Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 50M to $ 283M and net income went from -$ 102M to $ 287M. Revenue increased in every one of those 5 years; net income in every one.

Across Aurinia Pharmaceuticals Inc's full reported history, from 1999 to 2025, revenue grew from $ 1M to $ 283M and net income went from -$ 1M to $ 287M. Revenue increased in 52% of the years measured; net income in 48%.

Aurinia Pharmaceuticals Inc currently holds a 20-year HDB Score of 4.8 out of 10. How the HDB Score is calculated.

Membership

Continue AUPHโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,187 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies